Rare Diseases

Latest News

Efanesoctocog alfa Prophylaxis Offers “Efficacious Prevention” to Children With Severe Hemophilia A
Efanesoctocog alfa Prophylaxis Offers “Efficacious Prevention” to Children With Severe Hemophilia A

July 18th 2024

The drug was FDA approved as antihemophilic factor (recombinant), Fc-VWF-XTEN Fusion Protein-ehtl (Altuviiio) in February 2023.

Amgen Gains FDA Approval for First Interchangeable Biosimilar to Eculizumab
Amgen Gains FDA Approval for First Interchangeable Biosimilar to Eculizumab

May 29th 2024

FDA Approves Mavorixafor for Treatment of WHIM Syndrome
FDA Approves Mavorixafor for Treatment of WHIM Syndrome

April 29th 2024

FDA Approves Pfizer’s Gene Therapy for Hemophilia B
FDA Approves Pfizer’s Gene Therapy for Hemophilia B

April 26th 2024

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine
FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

April 16th 2024

Video Interviews
© 2024 MJH Life Sciences

All rights reserved.